HOTH Rocket One Inc.
Price Chart
Executive Summary
Rocket One Inc. (RKTO) filed a 424B5 prospectus supplement to increase its at-the-market (ATM) offering by up to $2.66 million in common stock, bringing total potential gross proceeds under the existing Sales Agreement with H.C. Wainwright to approximately $9.3 million. The company has already sold 6.8 million shares for ~$6.6 million under this agreement, and the new tranche represents ~19% dilution relative to the current public float of ~20.5 million shares. This is a dilutive capital raise for a micro-cap pharmaceutical company with a $14M market cap, signaling ongoing cash needs.
Actionable Insight
The ATM expansion signals continued cash burn and reliance on equity financing for a micro-cap pharma. Traders should expect near-term selling pressure as shares are placed into the market. Monitor for any pipeline catalysts or operational updates that could offset dilution concerns.
Key Facts
- Rocket One is offering up to an additional $2,661,176 of common stock under an existing ATM Sales Agreement with H.C. Wainwright.
- Since November 2024, the company has already sold 6,824,327 shares for gross proceeds of ~$6.6 million under the same agreement.
- The offering is limited by General Instruction I.B.6 of Form S-3 to one-third of public float ($27.8M) in any 12-month period.
- As of May 27, 2026, the company had 21,022,498 shares outstanding, with a public float of 20,468,902 shares.
- The stock closed at $1.36 per share on May 27, 2026, giving the company a market cap of ~$14M.
- The filing is an amendment to a prior S-3 shelf registration (File No. 333-291566) and prospectus supplement dated April 16, 2026.
Financial Impact
Up to $2.66 million in additional gross proceeds from new share sales; potential dilution of ~19% relative to current public float if fully sold at $1.36/share.
Risk Factors
- Further dilution if the full $2.66M is sold, increasing share count by up to ~1.96 million shares at current price.
- Ongoing cash burn without clear revenue or near-term catalyst may lead to additional future offerings.
- Micro-cap pharma with $14M market cap is highly sensitive to equity issuance; stock could trade lower as ATM shares hit the market.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001213900-26-061613 |
| Document: 0001213900-26-061613-index-headers.html | 0001213900-26-061613 |
| Document: 0001213900-26-061613-index.html | 0001213900-26-061613 |
| Document: 0001213900-26-061613.txt | 0001213900-26-061613 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
6d ago
|
8-K
| $2.14 $1.98 | ▼ −7.43% | ▼ −7.83% | $1.29 (−39.72%) |
|
Jun 3, 2026
6d ago
|
8-K
| $2.14 $1.98 | ▲ +7.43% | ▲ +7.83% | $1.29 (+39.72%) |
|
Jun 3, 2026
6d ago
|
424B5
| $2.14 $1.98 | ▲ +7.43% | ▲ +7.83% | $1.29 (+39.72%) |
|
Jun 2, 2026
7d ago
|
8-K
| $2.14 $1.97 | ▼ −7.94% | ▼ −8.34% | $1.29 (−39.72%) |
|
May 28, 2026
12d ago
|
8-K
| $1.70 $1.46 | ▼ −14.12% | ▼ −14.36% | $1.29 (−24.12%) |
|
May 27, 2026
13d ago
|
424B5
| $1.70 $1.46 | ▲ +14.12% | ▲ +14.36% | $1.29 (+24.12%) |
|
May 27, 2026
13d ago
|
8-K
| $1.36 $1.70 | ▲ +25.00% | ▲ +24.45% | $1.29 (−5.15%) |
|
May 4, 2026
5w ago
|
8-K
| $0.7100 $0.7400 | ▼ −4.23% | ▼ −2.84% | $1.29 (−81.69%) |
|
Apr 16, 2026
7w ago
|
8-K
| $0.7300 $0.7440 | ▲ +1.92% | ▲ +2.11% | $1.29 (+76.71%) |
|
Apr 16, 2026
7w ago
|
424B5
| $0.7300 $0.7440 | ▼ −1.92% | ▼ −2.11% | $1.29 (−76.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access